Abstract
Introduction
Academic research institutions are a rich source of technology for commercial
biomarker development. Some of today' s most dynamic biomarker discoveries
originated from academic-industrial relationships, resulting in millions of
dollars for universities and billions of dollars for industry. Alliances
between academia and industry can be complex, but creating a win-win solution
for both parties is possible and worthwhile.
Get the Answers You Need to Shape Your Strategy
- Most of the major players in the pharmaceutical industry are involved "
in some type of relationship with academic partners, and many successful
biomarkers ultimately derive from academic research. What are the key
alliances between academia and industry relevant to biomarker discovery and
diagnostic test development? What is the role of government oversight in
ensuring the success of these alliances?
- Various relationships exist between academic institutions and industry
engaged in biomarker development. What are the most common types of
partnerships between academia and industry? What are the risks and benefi ts
of each?
- Industrial science and academic science have fundamentally different
orientations, as well as different cultures and rules of conduct. What are the
issues to consider before embarking on a partnership? What are the ingredients
for a successful industry-academia relationship? What issues can sour a
relationship?
Scope
- Commercial biomarker development: creating a win-win for academia
and industry; the negotiation process; caveats for successful relationships.
- Types of academia-industry relationships: sponsorship,
consultation, consortia, partnerships and collaborations, and spin-outs.
- Case studies: a partnership that succeeded and another that did
not. What went right and what went wrong?
- Global perspective: Select academia-industry biomarker development
partnerships around the world.
View Cart
